A Single-Center, Non-Randomized, Open-Label, Parallel Group, Two-Treatment Study Investigating the Absolute Oral Bioavailability of Balovaptan After Single and Multiple Daily Oral Doses of Balovaptan in Healthy Volunteers
Latest Information Update: 13 Sep 2021
At a glance
- Drugs Balovaptan (Primary) ; Balovaptan (Primary)
- Indications Autistic disorder; Pervasive child development disorders
- Focus Pharmacokinetics
- Sponsors Roche
- 01 Aug 2021 Results of the early-phase pharmacokinetics from pooled data of two phase I studies ( NCT03764449 and NCT01418963) published in the Expert Opinion on Investigational Drugs
- 03 Jun 2019 Status changed from active, no longer recruiting to completed.
- 04 Mar 2019 Status changed from recruiting to active, no longer recruiting.